FDA says its review of abortion pill will continue into next year
- Posted on October 8, 2026
- By The Toronto Star
- 1 Views
- 1 min read
In brief
The Food and Drug Administration has announced that its comprehensive safety evaluation of mifepristone, the primary medication used for abortion procedures in the United States, will extend through the following year. This decision has generated immediate criticism from various stakeholders regarding the extended timeframe of the regulatory review process.
Summary auto-generated by AI from the original publisher's content. Editorial standards.
FDA says its review of abortion pill will continue into next year
WASHINGTON (AP) — The Food and Drug Administration says its ongoing safety review of the nation's main abortion pill will continue into next year, a timeline that was quickly condemned
